Clinical trials: Dendritic Cell
Pancreatic Cancer
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA.
- Trial name
- NCT00003434
- Testing
- carcinoembryonic antigen peptide 1, hepatitis B antigen peptide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Prostate Specific Antigens, Prostate Neoplasms
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Background: PSA (prostate specific antigen) is a protein found on normal and cancerous prostate cells. Levels of this protein are used to identify men who are at risk for prostate cancer and to monitor responses to treatment in…
- Trial name
- NCT00972309
- Testing
- T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals
This protocol aims to collect human peripheral blood mononuclear cells for the production of dendritic cells (DC). There are two ways to collect human peripheral blood mononuclear cells in this protocol.
- Trial name
- NCT00320164
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters)…
- Conditions
- Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT01487863
- Testing
- sipuleucel-T, abiraterone acetate
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Dendreon
Giant Cell Glioblastoma, Glioblastoma
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an…
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
- Trial name
- NCT01957956
- Testing
- Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Carcinoma, Renal Cell
Autologous Dendritic Cell Vaccine in Kidney Cancer
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
- Trial name
- NCT05127824
- Testing
- Autologous alpha-DC1/TBVA vaccine, Cabozantinib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jodi Maranchie
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003270
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma, Large B-Cell, Diffuse
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in…
- Trial name
- NCT03003520
- Testing
- Durvalumab, Rituximab, Doxorubicin
- Where
- 20 sites in United States, Austria and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Metastatic Melanoma
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in…
- Trial name
- NCT01876212
- Testing
- DC vaccine, Dasatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Walter J. Storkus
Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Large Cell Lymphoma Pilot Study III
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with…
- Trial name
- NCT00187070
- Testing
- Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma, Brain Tumor
Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma
The study induces an immune response towards the stem-cell like part of glioblastomas in combination with standard therapy. The aim is to define and characterize the feasibility, potential adverse effects of such therapy and…
- Trial name
- NCT00846456
- Testing
- Dendritic cell vaccine with mRNA from tumor stem cells
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Breast Cancer, Colorectal Cancer
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to the cancer cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00128622
- Testing
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Kim Lyerly
Prostatic Neoplasm, Prostate Cancer
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response.
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Trial name
- NCT01431391
- Testing
- sipuleucel-T, leuprolide acetate
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Dendreon
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003396
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Maryland, Baltimore
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and using drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002691
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme
Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection
1. Primary outcome measure: a.Evaluation of the treatment impact on progression-free survival. 2. Secondary outcome measures: 1. Safety evaluation. Direct effects attributable cell obtaining and administration.
- Trial name
- NCT01006044
- Testing
- autologous dendritic cells
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
DLBCL - Diffuse Large B Cell Lymphoma, Double Expressor Lymphoma
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Evaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
- Trial name
- NCT07511114
- Testing
- C-Pola-R-CHP+X, CR-CHOP
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Ruijin Hospital
Glioblastoma
Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme
Rationale of the Study: Treatment for GBM currently consists of surgical resection of the tumour mass followed by radio- and chemotherapy ((1)Stupp et al., 2005).
- Trial name
- DENDR1 (NCT04801147)
- Testing
- Dendritic Cells Vaccine
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Liver Metastasis, Gastric Cancer
Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
Objectives: The purpose of this study is to evaluate the safety and efficacy of PIK-HER2 cells in the treatment of advanced Her2 high expressed gastric cancer with liver metastasis patients.
- Trial name
- NCT02632201
- Testing
- PIK-HER2, DC-PMAT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Military Medical University
Renal Cell Carcinoma
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug that are known to target specific cells (in this case, cells in the immune system) The DC RCC Vaccine is agent that tries to help the…
- Trial name
- NCT01441765
- Testing
- CT-011, DC/RCC fusion vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Beth Israel Deaconess Medical Center